Eligible self-pay patients can fill oral semaglutide through GoodRx-participating pharmacies nationwide with transparent cash ...
Cell and gene therapies (CGTs) are reshaping the specialty pharmacy and distribution ecosystem, introducing a level of ...
In this week’s Pharma Pulse, the launch of the Ember Cube 2, exclusive policy insights from Asembia AXS26, a record-breaking ...
Scaling from ultra-rare volumes to mainstream indications threatens redundancy-heavy manufacturing and logistics, forcing redesign of distribution workflows to maintain chain-of-custody, integrity, ...
CoverMyMeds' Miranda Delatore and Megan Wetzel discuss AI in prior auth and fixing specialty access bottlenecks upstream. In ...
Will Shrank, MD, evaluates opportunities and challenges in specialty pharma over the next few years. In his interview with Pharmaceutical Commerce, live from Asembia AXS26 in Las Vegas, Will Shrank, ...
PBM reform is accelerating via FTC settlements and CAA 2026, mandating data reporting, rebate pass-through in Part D, de-linked fees, and constraints on spread pricing. Employer-sponsored plans may ...
Live from Asembia AXS26, Jessica Lovett explains what real world evidence and data matters most in making decisions around specialty medicines. In the first part of her interview with Pharmaceutical ...
Medicare-negotiated IRA prices are increasingly treated as de facto reference benchmarks in PBM contracting, with spillover potential beyond Medicare and implications for long-term asset value.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results